Avantor Inc.

Avantor, Inc. is a provider of mission critical products and services to customers in the biopharma, healthcare, education and government, and advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The firm operates through the following segments: the Americas, Europe, and AMEA. The company was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Avantor meets Q4 expectations, eyes bioproduction growth in 2023

Avantor delivered solid financial performance in Q4 and exceeded full-year revenue targets.
The company's focus on operational enhancements and global expansion supports future growth.
Challenges in the first quarter are being addressed with a focus on productivity and cost management.
Opportunities in bioproduction growth, M&A, and working capital improvements position Avantor for success.

Avantor Inc. reports Q1 revenue decline, eyes semiconductor market rebound

Avantor Inc. navigated challenges in Q1 with revenue declines due to destocking and semiconductor downturn, while showcasing strengths in innovation and acquisitions performance.
Management's confidence in the long-term strategy and focus on margin improvement present opportunities for growth and recovery in 2023, despite ongoing market challenges.
Strategic approaches to address destocking headwinds and market dynamics in different regions position Avantor Inc. for potential growth and resilience in the coming quarters.
Overall, Avantor Inc. faces challenges from market uncertainties but remains poised to leverage opportunities for growth, innovation, and margin improvement in the evolving landscape.

Avantor Inc. reports Q2 revenue decline, focuses on cost controls

Avantor Inc. faced revenue and EPS cuts in Q2 2023, driven by market challenges in biopharma and semiconductors. The company focused on cost savings, debt reduction, and operational efficiency. Challenges included limited visibility in research space and mid- to high single-digit organic decline in bioproduction.

Avantor Inc. reports Q3 revenue contraction, eyes growth opportunities

Avantor Inc. navigated challenges in Q3 2023 with a focus on growth and operational improvements.
Management's cautious yet optimistic stance reflects a strategic approach to customer sentiment and inventory health.
Outlook for 2024 remains uncertain, but the company is positioned to capitalize on opportunities in key markets.
Analyst questions addressed various topics, highlighting the company's proactive engagement with stakeholders.

Avantor Inc. exceeds Q4 expectations, eyes cost savings and margin growth

Avantor Inc. delivered solid Q4 results, focusing on executing business model transformation and driving growth strategy. Despite challenges in market conditions and revenue decline, the company is optimistic about cost-saving initiatives and margin improvement opportunities.

Avantor Inc. reports Q1 revenue decline but optimistic on growth

Avantor Inc. delivered mixed performance in Q1 2024 with revenue decline but strong margin and debt reduction. Despite challenges in certain segments and regions, the company remains optimistic about growth opportunities in key markets and cost-saving initiatives.

Avantor reports solid Q2 earnings, eyes growth in Bioprocessing segment

Avantor Inc.'s Q2 2024 performance showcased solid revenue, margin improvement, and strong segmental growth. While facing challenges in organic revenue decline and segmental performance, the company's focus on cost transformation and positive outlook signal resilience and potential for growth. Avantor's opportunities lie in leveraging Bioprocessing momentum and cost-saving initiatives for sustained performance enhancement.

Avantor Inc. reports solid Q3 performance and accelerates growth strategies

Avantor's Q3 performance reflects resilience and strategic focus amidst market challenges, with notable achievements in revenue, margin, and divestiture.
The company's strengths in innovation, operational excellence, and market positioning position it well for long-term growth and profitability.
While facing challenges in certain segments and cost transformation, Avantor's opportunities in renewable energy, cash flow, and market growth are promising.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Avantor, Inc. is a life science tools company that engages in providing mission-critical products and services to the life sciences and advanced technology industries. Its portfolio includes biopharma, healthcare, education and government, as well as advanced technologies and applied materials industries. It sells materials, equipment, instrumentation, and offers specialty procurement. The company operates through the following geographical segments: the Americas, Europe, and AMEA. Avantor was founded by John Townsend Baker in 1904 and is headquartered in Radnor, PA.

Bausch + Lomb Corp

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Avantor, Inc. (AVTR). But which of these two stocks offers value investors a better bang for their buck right now?

BLCO or AVTR: Which Is the Better Value Stock Right Now?

RADNOR, Pa. and LISBON, Portugal , Feb. 26, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, recognized supplier excellence across a range of categories and products at its 2024 European Sales Conference in Lisbon, Portugal earlier this month.

Avantor® Celebrates Supplier Award Honorees at 2024 European Sales Conference

Hanmi Financial

Cactus

HAFC, AVTR and WHD have been added to the Zacks Rank #5 (Strong Sell) List on February 20, 2024.

New Strong Sell Stocks for February 20th

RADNOR, Pa. , Feb. 20, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that Michael Stubblefield, President and CEO, will participate in a fireside chat at the 44th Annual TD Cowen Health Care Conference in Boston on Tuesday, March 5, 2024, at approximately 10:30 a.m.

Avantor® to Participate in the 44th Annual TD Cowen Health Care Conference

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft fourth-quarter performance.

Avantor (AVTR) Q4 Earnings & Revenues Top Estimates, Margins Down

Avantor, Inc. (AVTR) Q4 2023 Earnings Call Transcript

Although the revenue and EPS for Avantor, Inc. (AVTR) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Avantor, Inc. (AVTR) Q4 Earnings: A Look at Key Metrics

Fourth Quarter 2023 Net sales of $1.72 billion, decrease of 4.0%; core organic decline of 4.8% Net income of $98.5 million; Adjusted EBITDA of $302.1 million Diluted GAAP EPS of $0.15; adjusted EPS of $0.25 Operating cash flow of $251.6 million; free cash flow of $201.0 million Full Year 2023 Net sales of $6.97 billion, decrease of 7.3%; core organic decline of 5.2% Net income of $321.1 million; Adjusted EBITDA of $1,309.1 million Diluted GAAP EPS of $0.47; adjusted EPS of $1.06 Operating cash flow of $870.0 million; free cash flow of $723.6 million Adjusted net leverage of 3.9X; repaid approximately $850 million of debt in 2023 RADNOR, Pa. , Feb. 14, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for the fourth quarter and year ended December 31, 2023.

Avantor® Reports Fourth Quarter and Full Year 2023 Results

Besides Wall Street's top -and-bottom-line estimates for Avantor, Inc. (AVTR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2023.

Curious about Avantor, Inc. (AVTR) Q4 Performance? Explore Wall Street Estimates for Key Metrics

Elevance Health Inc

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Avantor, Inc. (AVTR). But which of these two companies is the best option for those looking for undervalued stocks?

ELV vs. AVTR: Which Stock Is the Better Value Option?

RADNOR, Pa. , Jan. 24, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February, 14, and will hold a conference call to discuss the results on the same day at 8:00 a.m.

Avantor® to Report Fourth Quarter and Full Year 2023 Earnings on Wednesday, February 14, 2024

RADNOR, Pa. , Jan. 19, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, kicked off the year at the 2024 Americas Sales Conference in Orlando, Fla.

Avantor® Recognizes Supplier Award Winners at 2024 Americas Sales Conference

RADNOR, Pa. , Jan. 3, 2024 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, announced that Michael Stubblefield, President and CEO, will present at the 42nd Annual J.P.

Avantor® to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Transformative New Operating Model to Feature Two Complementary Business Segments Aligned to Customer Needs: Laboratory Solutions and Bioscience Production  Company Launches Cost Optimization Initiative to Deliver $300M in Run Rate Savings by the end of 2026 Reaffirms Fiscal Year 2023 Guidance RADNOR, Pa. , Dec. 7, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the biopharma and healthcare, education and government, and advanced technologies industries, will host an Investor Day tomorrow to discuss the company's strategic growth plans.

Avantor® Hosts Investor Day, Announces New Strategic Operating Model to Drive Growth and Productivity

RADNOR, Pa. , Nov. 30, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries received a score of 100 on the Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index (CEI) and was recognized as an Equality 100 Award: Leader in LGBTQ+ Workplace Inclusion honoree.

Avantor® Receives Top Score on Human Rights Campaign Foundation's 2023-2024 Corporate Equality Index

RADNOR, Pa. , Nov. 22, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, announced that the company will host an Investor Day on December 8, 2023, at 9:00 a.m.

Avantor® to Host Investor Day on December 8, 2023

RADNOR, Pa. , Nov. 16, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, announced that President and CEO Michael Stubblefield, will be participating in a fireside chat at the Evercore ISI HealthCONx Conference in Miami, Florida on Tuesday, November 28, at 10:00 a.m.

Avantor® to Participate in the 6th Annual Evercore ISI HealthCONx Conference

Avantor's (AVTR) latest offerings are likely to provide its customers with products, materials and services that would aid in accelerating therapeutics.

Avantor's (AVTR) New Offerings to Aid Cell and Gene Therapy Suite

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.

Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top

Although the revenue and EPS for Avantor, Inc. (AVTR) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Compared to Estimates, Avantor, Inc. (AVTR) Q3 Earnings: A Look at Key Metrics

Avantor, Inc. (NYSE:AVTR ) Q3 2023 Earnings Conference Call October 27, 2023 8:00 AM ET Company Participants Christina Jones - VP, IR Michael Stubblefield - President & CEO Brent Jones - EVP & CFO Conference Call Participants Daniel Brennan - TD Cowen Vijay Kumar - Evercore ISI Jack Meehan - Nephron Research Michael Ryskin - Bank of America Patrick Donnelly - Citi Rachel Vatnsdal - JPMorgan Luke Sergott - Barclays Daniel Leonard - UBS Catherine Schulte - Robert W. Baird Operator Good morning.

Avantor, Inc. (AVTR) Q3 2023 Earnings Call Transcript

Avantor, Inc. (AVTR) came out with quarterly earnings of $0.25 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.34 per share a year ago.

Avantor, Inc. (AVTR) Q3 Earnings Meet Estimates

Net sales of $1.72 billion, decrease of 7.3%; core organic decline of 7.9% Net income of $108.4 million; Adjusted EBITDA of $317.8 million Diluted GAAP EPS of $0.16; adjusted EPS of $0.25 Operating cash flow of $230.7 million; free cash flow of $193.0 million Adjusted net leverage of 3.9X; repaid more than $650 million of debt year to date RADNOR, Pa. , Oct. 27, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, education and government, advanced technologies and applied materials industries, today reported financial results for the third quarter ended September 30, 2023.

Avantor® Reports Third Quarter 2023 Results

Catalent

Danaher

DexCom

Inspire Medical Systems Inc

Coca-Cola

Eli Lilly

Novo Nordisk

PepsiCo

Insulet

Repligen

Thermo Fisher Scientific

Walmart

Citing Vanda Research, the Wall Street Journal reports that the average individual-investor stock portfolio is up 150% since the start of 2014, versus around 140% for the S&P 500's SPX during the same period.

The weight-loss drugs are coming for these companies — but here's why Coke, others, may be spared, says JPMorgan

RADNOR, Pa. , Sept. 29, 2023 /PRNewswire/ -- Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences and technology industries, will release its third quarter 2023 financial results before the market opens on Friday, October 27, and will hold a conference call on the same day at 8:00 a.m.

News for Avantor Inc. Stock (AVTR)